Day: November 9, 2022

Announcement no. 15 COPENHAGEN, Denmark and BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) — BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first nine months of 2022 and business progress for the third quarter of 2022. Recent HighlightsFor the nine months ending September 30, 2022:Total revenue of DKK 20.3 million / USD 2.9 million, a 16% increase over the prior year Adjusted EBITDA of DKK (49.5) million / USD (7.2) million Cash and cash equivalents of DKK 98.9 million / USD 13.0 million as of September 30, 2022 (DKK 59.6 million / USD 9.3 million as of September 30, 2021)For the third quarter ending September 30, 2022:Total revenue of DKK 5.3 million / USD 0.7 million, a 0.4% decrease over the prior year Adjusted EBITDA of DKK (17.1) million / USD (2.3) millionBioPorto continues preparations...

November 9, 2022 Announcement no. 15 BioPorto Announces Interim Results for the First Nine Months of 2022 COPENHAGEN, Denmark and BOSTON, MA, USA, November 9, 2022, (GLOBE NEWSWIRE) — BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first nine months of 2022 and business progress for the third quarter of 2022. Recent HighlightsFor the nine months ending September 30, 2022:Total revenue of DKK 20.3 million / USD 2.9 million, a 16% increase over the prior year Adjusted EBITDA of DKK (49.5) million / USD (7.2) million Cash and cash equivalents of DKK 98.9 million / USD 13.0 million as of September 30, 2022 (DKK 59.6 million / USD 9.3 million as of September 30, 2021)For the third quarter ending September 30, 2022:Total revenue of DKK 5.3 million / USD 0.7 million, a 0.4% decrease over the...

Access to up to $400 million expected to provide cash runway through at least 2025 Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended September 30, 2022, and provides a corporate update. “We have significantly strengthened our financial position with access up to approximately $400 million, through our cash on hand and recently announced $150 million debt facility from Oxford Finance,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer. “We expect these funds to extend our cash runway...

COPENHAGEN, Denmark, November 9, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2022 and business progress for the third quarter of 2022. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “These are exciting times for Bavarian Nordic as we have continued to expand our activities to support the global response against monkeypox, while also running two global Phase 3 trials of our late-stage pipeline assets. We are highly encouraged to see how our vaccines can truly make a difference by providing comfort for the populations at-risk and helping to change the course of the monkeypox outbreak. More than 1 million people have received our vaccine since the beginning of the outbreak and the number grows day by day and we have already secured significant...

Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding the interim financial report for the 3rd quarter of the 2022 financial year. Press release ENCommuniqué de presse FRPersbericht NL

Press Release November 9, 2022 – N° 17 First nine months 2022 results SCOR takes action to restore profitability in a challenging environmentGross written premiums of EUR 14,827 million in the first nine months of 2022, up 6.2%1 compared with 9M 2021 Net loss of EUR -509 million in the first nine months of 2022, compared with EUR 339 million net income in 9M 2021 Shareholders’ equity of EUR 5,430 million at the end of September 2022, implying a book value per share of EUR 30.39, down -13.8% from December 2021 (EUR 35.26) Estimated solvency ratio of 217% at the end of September 2022, at the high end of SCOR’s optimal rangeSCOR SE’s Board of Directors met on November 8, 2022, under the chairmanship of Denis Kessler, to approve the Group’s first nine months 2022 financial statements2. Key highlights: In the third quarter...